- Home
- SGD vs SCNI Comparison
SGD vs SCNI Comparison
Compare SGD & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- SCNI
- Stock Information
- Founded
- SGD 2021
- SCNI 2003
- Country
- SGD United States
- SCNI Israel
- Employees
- SGD N/A
- SCNI N/A
- Industry
- SGD
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGD
- SCNI Health Care
- Exchange
- SGD Nasdaq
- SCNI Nasdaq
- Market Cap
- SGD 3.4M
- SCNI 3.5M
- IPO Year
- SGD N/A
- SCNI N/A
- Fundamental
- Price
- SGD $2.22
- SCNI $3.48
- Analyst Decision
- SGD
- SCNI
- Analyst Count
- SGD 0
- SCNI 0
- Target Price
- SGD N/A
- SCNI N/A
- AVG Volume (30 Days)
- SGD 131.4K
- SCNI 13.2K
- Earning Date
- SGD 01-01-0001
- SCNI 11-22-2024
- Dividend Yield
- SGD N/A
- SCNI N/A
- EPS Growth
- SGD N/A
- SCNI N/A
- EPS
- SGD N/A
- SCNI 8.20
- Revenue
- SGD $173,188.00
- SCNI $452,000.00
- Revenue This Year
- SGD N/A
- SCNI N/A
- Revenue Next Year
- SGD N/A
- SCNI N/A
- P/E Ratio
- SGD N/A
- SCNI $0.42
- Revenue Growth
- SGD N/A
- SCNI N/A
- 52 Week Low
- SGD $1.45
- SCNI $2.23
- 52 Week High
- SGD $53.80
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- SGD 40.85
- SCNI 56.32
- Support Level
- SGD $2.05
- SCNI $3.20
- Resistance Level
- SGD $2.40
- SCNI $3.55
- Average True Range (ATR)
- SGD 0.24
- SCNI 0.18
- MACD
- SGD 0.05
- SCNI 0.03
- Stochastic Oscillator
- SGD 26.32
- SCNI 51.72
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.